SnoRNAs and miRNAs Networks Underlying COVID-19 Disease Severity

Parray, Aijaz; Mir, Fayaz Ahmad; Doudin, Asmma; Iskandarani, Ahmad; Danjuma, Mohammed; R, Kuni; Abdelmajid, Alaaeldin; Abdelhafez, Ibrahim; Arif, Rida; Mulhim, Mohammad; Abukhattab, Mohammed; Dar, Shoukat Rashhid; Moustafa, Ala-Eddin Al; Elkord, Eyad; Khal, Abdul Latif Al; Elzouki, Abdel‐Naser; Cyprian, Farhan S.

doi:10.3390/vaccines9101056

Cited by 30 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of T follicular helper cells in germinal centers indicates active affinity maturation with diverse antibody production conferring enhanced protection [ 33 , 34 ]. Indeed, publications from our group [ 35 , 36 ] and several others have shown a direct correlation of decreased lymphocyte count with COVID-19 severity and mortality, while higher lymphocyte counts confer protection [ 37 , 38 , 39 ]. Interestingly, increased pro-inflammatory myeloid cells in the lung tissue and peripheral blood correlate with mortality and age [ 40 ].…”

Section: Discussionmentioning

confidence: 95%

Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease

et al. 2022

View full text Add to dashboard Cite

Waning immunity following administration of mRNA-based COVID-19 vaccines remains a concern for many health systems. We undertook a study to determine if recent reports of waning for severe disease could have been attributed to design-related bias by conducting a study only among those detected with a first SARS-CoV-2 infection. We used a matched case-control study design with the study base being all individuals with first infection with SARS-CoV-2 reported in the State of Qatar between 1 January 2021 and 20 February 2022. Cases were those detected with first SARS-CoV-2 infection requiring intensive care (hard outcome), while controls were those detected with first SARS-CoV-2 infection who recovered without the need for intensive care. Cases and controls were matched in a 1:30 ratio for the calendar month of infection and the comorbidity category. Duration and magnitude of conditional vaccine effectiveness against requiring intensive care and the number needed to vaccinate (NNV) to prevent one more case of COVID-19 requiring intensive care was estimated for the mRNA (BNT162b2/mRNA-1273) vaccines. Conditional vaccine effectiveness against requiring intensive care was 59% (95% confidence interval (CI), 50 to 76) between the first and second dose, and strengthened to 89% (95% CI, 85 to 92) between the second dose and 4 months post the second dose in persons who received a primary course of the vaccine. There was no waning of vaccine effectiveness in the period from 4 to 6, 6 to 9, and 9 to 12 months after the second dose. This study demonstrates that, contrary to mainstream reports using hierarchical measures of effectiveness, conditional vaccine effectiveness against requiring intensive care remains robust till at least 12 months after the second dose of mRNA-based vaccines.

show abstract

Section: Discussionmentioning

confidence: 95%

Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As mentioned above, hsa-miR-1246 not only discriminated critical COVID-19 patients versus COVID-19-negative controls, it also allowed to distinguish critical versus asymptomatic patients, in agreement with a recent study in which has-miR-1246 appeared differentially expressed in severe versus asymptomatic COVID-19 patients, although this study was performed only with male patients. 46 Notablhashsa-miR-1246 has been described as a biomarker of emphysema in patients with chronic obstructive pulmonary disease, 47 and also with nonsmall cell lung cancer progression. 48 Moreover, miR-1246 has been identified as a possible regulator of the SARS-CoV-2 genome, which would provide more information on the protection mechanisms associated with miRNAs.…”

Section: Discussionmentioning

confidence: 99%

Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients

Calderón‐Domínguez¹,

Trejo²,

González-Rovira³

et al. 2022

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

“…Some recent studies have started to shed light on the involvement of miRNAs in SARS-CoV-2 infection, with most of these studies being based on computational prediction and in silico analyses [33]. A few experimental studies on the expression of miRNAs in patients with COVID-19 have been performed [34][35][36][37][38][39][40][41][42][43][44][45]. Whereas these studies have investigated miRNA expression in the blood, our study and a recently published study by Eichmeier and colleagues [46] are the first to investigate the miRNA expression profile in nasopharyngeal swabs of COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

Altered microRNA expression in severe COVID-19: potential prognostic and pathophysiological role

Garnier

Pollet

Fourcot

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is ongoing. The pathophysiology of SARS-CoV-2 infection is beginning to be elucidated but the role of microRNAs (miRNAs), small non-coding RNAs that regulate gene expression, remains incompletely understood. They play a role in the pathophysiology of viral infections with potential use as biomarkers. The objective of this study was to identify miRNAs as biomarkers of severe COVID-19 and to analyze their role in the pathophysiology of SARS-CoV-2 infection. Methods miRNA expression was measured in nasopharyngeal swabs from 20 patients with severe COVID-19, 21 patients with non-severe COVID-19 and 20 controls. Promising miRNAs to differentiate non-severe from severe COVID-19 patients were identified by differential expression analysis and sparse Partial Least Squares-Discriminant Analysis (sPLS-DA). ROC analysis, target prediction, GO enrichment and pathway analysis were used to analyze the role and the pertinence of these miRNAs in severe COVID-19. Results The number of expressed miRNAs was lower in severe COVID-19 patients compared to non-severe COVID-19 patients and controls. Among the differentially expressed miRNAs between severe COVID-19 and controls, 5 miRNAs were also differentially expressed between severe and non-severe COVID-19. sPLS-DA analysis highlighted 8 miRNAs, that allowed to discriminate the severe and non-severe COVID-19 cases. Target and functional analysis revealed enrichment for genes involved in viral infections and the cellular response to infection as well as one miRNA, hsa-miR-15b-5p, that targeted the SARS-CoV-2 RNA. The comparison of results of differential expression analysis and discriminant analysis revealed three miRNAs, namely hsa-miR-125a-5p, hsa-miR-491-5p and hsa-miR-200b-3p. These discriminated severe from non-severe cases with areas under the curve ranging from 0.76 to 0.80. Conclusions Our analysis of miRNA expression in nasopharyngeal swabs revealed several miRNAs of interest to discriminate severe and non-severe COVID-19. These miRNAs represent promising biomarkers and possibly targets for antiviral or anti-inflammatory treatment strategies.

show abstract

SnoRNAs and miRNAs Networks Underlying COVID-19 Disease Severity

Cited by 30 publications

References 35 publications

Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease

Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease

Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients

Altered microRNA expression in severe COVID-19: potential prognostic and pathophysiological role

Contact Info

Product

Resources

About